Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 2.523B
March 31, 2026 2.523B
December 31, 2025 2.523B
September 30, 2025 2.523B
June 30, 2025 2.523B
March 31, 2025 2.523B
December 31, 2024 2.523B
September 30, 2024 2.523B
June 30, 2024 2.523B
March 31, 2024 2.523B
December 31, 2023 2.523B
September 30, 2023 2.523B
June 30, 2023 2.523B
March 31, 2023 2.523B
December 31, 2022 2.523B
September 30, 2022 2.523B
June 30, 2022 2.340B
March 31, 2022 2.340B
December 31, 2021 2.340B
September 30, 2021 2.279B
June 30, 2021 2.279B
March 31, 2021 1.179B
September 30, 2010 181.21M
September 30, 2007 62.88M
June 30, 2007 62.88M
Date Value
March 31, 2007 63.04M
December 31, 2006 63.04M
September 30, 2006 61.91M
June 30, 2006 58.64M
March 31, 2006 58.64M
December 31, 2005 57.23M
September 30, 2005 56.06M
June 30, 2005 56.06M
March 31, 2005 47.66M
December 31, 2004 45.21M
September 30, 2004 38.22M
June 30, 2004 37.87M
March 31, 2004 37.87M
December 31, 2003 35.17M
September 30, 2003 34.37M
June 30, 2003 33.62M
March 31, 2003 33.62M
December 31, 2002 31.77M
September 30, 2002 19.89M
June 30, 2002 15.88M
March 31, 2002 15.88M
December 31, 2001 10.52M
September 30, 2001 6.690M
June 30, 2001 6.566M
March 31, 2001 6.536M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Biomerica, Inc. 3.195M
Lantheus Holdings, Inc. 65.26M
Zomedica Corp. 979.95M
IDEXX Laboratories, Inc. 78.87M
Neogen Corp. 217.70M